Ilhan, NiluferCoskun, MesutIlhan, OzgurTuzcu, Esra AyhanDaglioglu, Mutlu CihanElbeyli, AhmetKeskin, Ugurcan2024-09-182024-09-1820151556-95271556-9535https://doi.org/10.3109/15569527.2014.975242https://hdl.handle.net/20.500.12483/7732Objective: To evaluate the effects of dexamethasone (DEX) implant (Ozurdex(R)) on corneal endothelium in patients with retinal vein occlusion complicated with macular edema. Materials and methods: Patients (n = 31) received 1-3 intravitreal DEX implants in one eye. Measurements were intraocular pressure (IOP) at baseline and 1, 3, and 6 months after the first intravitreal injection and corneal specular microscopy and central corneal thickness (CCT) at baseline and 1 and 6 months. We analyzed endothelial cell density (ECD), coefficient of variation of cell size (CV), and percentage of hexagonality. Results: Mean follow-up period was 9.7 +/- 3.3 months. Mean number of injections was 1.5 +/- 0.8. Mean IOP values were 15.6 +/- 2.6mm Hg at baseline, 17.7 +/- 3.6mm Hg at one month, 16.4 +/- 4.1mm Hg at three months, and 16.0 +/- 2.7mm Hg at six months. There was a significant difference in mean IOPs at one month and six months (p = 0.008). There were no significant differences in mean ECD (p = 0.375), CV (p = 0.661), percentage of hexagonality (p = 0.287), and CCT (p = 0.331). Conclusion: Although intravitreal injection of 0.7mg DEX causes moderate elevation of IOP, it does not seem to have detrimental effects on corneal endothelium at six months.eninfo:eu-repo/semantics/closedAccessAnterior eye segmentcorticosteroiddrug delivery systemsArticle34429429710.3109/15569527.2014.975242253477992-s2.0-84946064763Q3WOS:000371395000006Q4